Drug intelligence / Profile preview

LCAR-B4822M

Development stage: Phase 1
Lead developer: Nanjing Legend Biotech
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

LCAR-B4822M is an autologous chimeric antigen receptor T cell (CAR-T) therapy in which a patient's own peripheral blood T lymphocytes are genetically modified to express a CAR targeting B-cell maturation antigen (BCMA). The engineered T cells are designed to recognize and bind BCMA on the surface of malignant plasma cells, leading to their destruction through cytotoxic mechanisms. This therapy is being developed primarily for the treatment of relapsed or refractory multiple myeloma. The drug is in early clinical development and has been evaluated in phase 1 trials for patients with relapsed/refractory multiple myeloma[1][2][4].

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on LCAR-B4822M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LCAR-B4822M.

Explore the full profile